@article{Cunningham_S-2024_202087,
title = {Update to: Study Pre-protocol for "BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study"},
author = {Cunningham, S. and Mpamhanga, C. and Swann, O. and Drysdale, S. and Liu, X. and Groves, H. and O'Hagan, S. and Waterfield, T. and Iskander, D. and Lyttle, M. and Marlow, R. and Maxwell-Hodkinson, A. and Sinha, I. and Roland, D. and Williams, T.},
month = {dec},
year = {2024},
abstract = {BACKGROUND: In 2021 we launched the BronchStart study, which collected information on 17,899 presentations in children with serious respiratory tract infections following the release of lockdown restrictions. Our study informed the Joint Committee on Vaccination and Immunisation's decision to recommend the introduction maternal respiratory syncytial virus (RSV) vaccination, which was introduced in the United Kingdom in August/September 2024.},
volume = {6},
journal = {Wellcome Open Research},
publisher = {F1000 Research},
url = {https://doi.org/10.12688/wellcomeopenres.16778.4},
}
